ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; CKD = chronic kidney disease; CRT = cardiac resynchronisation therapy; EF = ejection fraction; GFR = glomerular filtration rate; HF = heart failure; HF(P/R)EF = HF (with preserved/reduced) EF; HR = hazard ratio; LA/V = left atrial/ventricular; LBBB = left bundle branch block; NGAL = neutrophil gelatinase-associated lipocalin; NYHA = New York Heart Association.
Neutrophil gelatinase-associated lipocalin for acute kidney injury during acute heart failure hospitalizations Authors: Maisel AS et al.
Summary:
The prospective AKINESIS study enrolled 927 patients presenting with acute HF requiring intravenous diuretic agents to assess if plasma NGAL (neutrophil gelatinase-associated lipocalin) levels were able to predict worsening renal failure (increase in plasma creatinine level of 0.5 mg/dL or ≥50%) within the first 5 days of hospitalisation, which occurred in 72 participants. Although peak NGAL level was more predictive than the first NGAL level, neither added significant diagnostic utility to first creatinine level (respective areas under the ROC curves 0.656, 0.647 and 0.652). Similarly, first creatinine level was similar to first and peak NGAL levels for predicting in-hospital adverse events (respective areas under the ROC curves 0.686, 0.691 and 0.653), of which there were 235 events affecting 144 participants. A post hoc analysis of participants with an estimated GFR of <60 mL/min/1.73m 2 revealed that a first NGAL level of <150 ng/mL was indicative of a low likelihood of adverse events.
Comment: Given that serum creatinine level increases 1-3 days after renal injury, this large multicentre study evaluated whether the tubular marker NGAL would be a more reliable marker of subsequent worsening renal failure in acute HF patients receiving (or about to receive) intravenous diuretics. The failure of plasma NGAL level to provide incremental risk prediction beyond serum creatinine level may reflect the multifactorial contributors to both worsening renal failure and plasma NGAL level itself (including renal and nonrenal production), and also questions whether increases in serum creatinine level in this setting actually represent worsening renal function in most patients. Meanwhile the results for urinary NGAL are awaited.
Reference: J Am Coll Cardiol 2016; 68(13):1420-31 Abstract Transvenous neurostimulation for central sleep apnoea Authors: Costanzo MR et al., for the remedé System Pivotal Trial Study Group Summary: Medically stable adults with central sleep apnoea with an apnoea-hypopnoea index of ≥20 events per hour were implanted with a device that transvenously stimulates a nerve causing diaphragmatic contraction similar to normal breathing, and were randomised to device stimulation (n=73) or no stimulation (n=78) for 6 months.
In an intent-to-treat analysis, a significantly greater proportion of the device simulation group than control group had a reduction in apnoea-hypopnoea index of ≥50% at 6 months (51% vs. 11% [p<0.0001]), with similar procedure-related serious adverse event rates (8% vs. 9%). None of the seven deaths during the study were considered to be related to implantation, system or therapy. Therapy-related discomfort was reported by 37% of the device stimulation group, and this resolved with system reprogramming in all but one of the affected participants.
Comment: Unilateral, phrenic nerve stimulation is a novel approach to treating central sleep apnoea, with previous single-arm studies reporting safety and clinical efficacy. This randomised controlled trial met its primary efficacy and safety endpoints, and the treatment was well tolerated. Approximately two-thirds of the patients had a prior history of HF with similar benefits reported in these patients. Future larger studies will need to determine whether this approach improves hard clinical outcomes.
Reference : Lancet 2016; 388(10,048):974-82 Abstract Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure Authors: Johansson I et al. Summary: The effects of ischaemic versus nonischaemic HF and previous revascularisation on long-term prognosis in the presence versus absence of type 2 diabetes were explored in 35,163 Swedish HF registry patients; 90% of the patients had ≥1 associated comorbidity; 62% and 47% had ischaemic heart disease with and without type 2 diabetes, respectively, of whom 53% and 48% had previously undergone revascularisation. The presence of type 2 diabetes was associated with an increased likelihood of death in patients with and without ischaemic heart disease (respective adjusted HRs 1.40 [95% CI 1.33-1.46] and 1.30 [1.22-1.39]). The mortality risk was greatest in patients with both type 2 diabetes and ischaemic heart disease, but was lowered by revascularisation, even after propensity score adjustment Comment: This study confirms that diabetes is an independent, adverse prognostic marker in HF. Sixty-two percent of HF patients with diabetes had ischaemic heart disease, with these patients having a particularly high mortality, which was partially offset by prior revascularisation. Given the lower mortality observed at 10 years follow-up in patients randomised to receive coronary artery bypass surgery in the STICH trial, this reinforces the need to consider investigations to rule out significant coronary artery disease in HF patients, especially in those with diabetes.
Reference: J Am Coll Cardiol 2016;68(13):1404-16 Abstract
Independent commentary by Dr. John Atherton, Director of Cardiology at the Royal Brisbane and Women's Hospital, Associate Professor, University of Queensland and Adjunct Professor, Queensland University of Technology. He previously chaired the Asia-Pacific Acute Decompensated Heart Failure Registry SAC and the CSANZ Heart Failure Council. He has been an appointed member of the Australian Government Medical Services Advisory Committee and sat on the National Heart Foundation Heart Failure Guidelines executive writing group. Research interests include investigating novel methods to detect presymptomatic cardiac disease and cardiac genetics. Contributions to statewide service enhancement include coordinated heart failure disease management and co-establishing a cardiac genetics service. Risk reduction of CV death in combination with standard therapy in patients with evidence of heart failure and left ventricular impairment within 3-14 days of an acute myocardial infarction; Risk reduction of CV mortality and morbidity in adults with NYHA Class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF ≤30% or LVEF ≤35% in addition to QRS duration of > 130 msec), in addition to standard optimal therapy. Contraindications: Hypersensitivity to eplerenone or any of the excipients, clinically significant hyperkalaemia, chronic kidney disease stages 4 and 5, severe hepatic insufficiency, co-administration of potassium-sparing diuretics or strong inhibitors of CYP3A4. Precautions: Hyperkalaemia, potassium supplements or salt substitutes containing potassium, chronic kidney disease, impaired hepatic function, pregnancy, lactation, paediatric use, use in elderly, driving and use of machinery. See PI for details. Interactions with Other Medicines: Inhibitors/inducers of CYP3A4; ACE inhibitors; angiotensin receptor blockers, lithium; cyclosporin; tacrolimus; trimethoprim; alpha-1-blockers; tricyclic anti-depressants; neuroleptics; amifostine; baclofen; NSAIDs. See PI for details. Adverse Effects: Common: hyperkalaemia, myocardial infarction, diarrhoea, nausea, constipation, infection, dehydration, musculoskeletal pain, dizziness, hypotension, syncope, renal impairment, cough, pruritis; Serious but not common: left sided cardiac failure, tachycardia, hypothyroidism, cholecystitis, blood glucose increased. Serious post-marketing: angioedema, rash. See PI for details. Dosage and Administration: Initiate treatment at 25 mg once daily and titrate to the target dose of 50 mg once daily within 4 weeks, taking into account serum potassium levels. Patients with baseline eGFR 30-50 mL/min/1.73 m 2 , initial dose should be 25 mg every other day, titrated to maximum of 25 mg daily. Serum potassium should be measured before initiating and during INSPRA therapy, particularly in patients with chronic kidney disease, and the dose adjusted as required. See Comment: Our current approach to treating HFREF is largely based on clinical trials with a predominance of middle-aged, white men. This study based on two population-based HF registries reports that Asian (compared with white) HF patients had slightly shorter QRS duration (as expected); however in adjusted analyses, Asian (compared with white) HFREF patients had longer QRS duration with a steeper inverse relationship between LVEF and QRS duration. Whilst these findings are hypothesis-generating, they nonetheless highlight the limitations of our current simplistic approach to categorising HF management based on variables such as LVEF and QRS duration, which vary according to age, sex and ethnicity.
Reference: Heart 2016;102(18):1464-71 Abstract
Differential response to low-dose dopamine or low-dose nesiritide in acute heart failure with reduced or preserved ejection fraction Authors: Wan S-H et al.
Summary:
This post hoc analysis of 360 ROSE AHF trial participants with acute HF and renal dysfunction evaluated interactions between treatment effect and EF. Variations were seen for the effects of dopamine and nesiritide on urine volume according to EF (respective p values for interaction 0.001 and 0.039), with HFREF and HFPEF patients having greater and lower urine volumes, respectively, with active treatment versus placebo. There were also variations by EF for the effects of dopamine and nesiritide on bodyweight change, sodium excretion and incidence of acute HF treatment failure (p<0.05 for all interactions), but no interaction on change in cystatin-C level. Dopamine was associated with better clinical outcomes in HFREF and worse ones in HFPEF compared with placebo, whereas for nesiritide versus placebo, no differences in clinical outcomes were seen between participants with HFPEF and those with HFREF.
Comment: Given that the ROSE AHF trial did not achieve its primary endpoint, these results should be regarded as hypothesis-generating. The opposing effects of low-dose dopamine in HFREF (benefit) and HFPEF (harm) could represent the play of chance, although are biologically plausible. Pending further investigation, this suggests that low-dose dopamine may have a role in acute HF patients with a reduced LVEF, renal dysfunction and persisting congestion despite intravenous (preferably high-dose) diuretic therapy. However, clinicians should bear in mind that even at this so-called 'low-dose', patients experienced higher heart rates with dopamine (reported in the original study publication), suggesting a β-agonist effect (and therefore the potential for proarrhythmia).
Reference: Circ Heart Fail 2016;9:e002593 Abstract
Non-invasive lung IMPEDANCE-guided preemptive treatment in chronic heart failure patients Comment: This single-blind study demonstrated a significant reduction in the primary endpoint (acute HF hospitalisations) as well as significant reductions in all-cause mortality (driven by reductions in HF death) associated with treatment adjusted according to noninvasive measurement of lung impedance performed by technicians at outpatient clinics. These findings contrast with the DOT-HF and OptiLink HF studies, which used OptiVol to measure intrathoracic impedance. The authors suggest that their technique is more sensitive given that it measures net lung (rather than total transthoracic) impedance. Whilst this technology is promising, the intervention was resource-intense with scheduled monthly outpatient hospital clinic visits. These findings require confirmation, and ideally better delineation of which patients will gain most benefit from this technology.
Reference: J Card Fail 2016; 22(9) 2 ) receiving chronic ACE inhibitor/ARB treatment. No significant relationship was seen between change in estimated GFR and baseline ACE inhibitor/ARB dose or relative or absolute change of ACE inhibitor/ARB dose during follow-up. Similar results were seen when renal function was expressed as a categorical variable (improved/stable/decreased) or in subgroup analyses with respect to age, sex, NYHA functional class, LVEF, diabetes, concomitant aldosterone antagonists, CKD stage, hypertension, ACE inhibitor versus ARB use and congestion status. Neither ACE inhibitor/ARB dose nor dose change was associated with worsening CHF or hyperkalaemia.
Comment: Randomised controlled trials evaluating the efficacy of ACE inhibitors/ARBs in HFREF excluded patients with severe CKD. This study provides some reassurance that neither the dose of ACE inhibitor/ARB nor uptitration of these agents was associated with longer term worsening of renal function in HFREF patients with stage III/IV CKD. However, important caveats are that the patients selected had all been on treatment for at least 1 month, and that they were closely monitored in an HF clinic setting.
Reference: Am Heart J 2016; 178:28-36 Abstract
